Differences in pharmacokinetics may account for the trend toward lower HIV infection rates with FTC/TAF vs FTC/TDF as PrEP in MSM and transgender women enrolled on the phase III DISCOVER trial.
CCO slides from Drs. Judith Feinberg and Kenneth Mayer on ending the HIV epidemic by overcoming barriers to the use of HIV PrEP among at-risk groups
CCO video module: Drs. Judith Feinberg and Kenneth Mayer on ending the HIV epidemic by overcoming barriers to the use of HIV PrEP among at-risk groups
Clinical Care Options (CCO) presenta las reflexiones de la Dra. Leticia M. Pérez Saleme sobre cómo ha cambiado la atención de pacientes con VIH durante la pandemia de COVID-19 en México.
Multimedia module from Clinical Care Options: HIV experts review new/emerging strategies for initial HIV treatment, switching ART, and HIV prevention